StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Insight Molecular Diagnostics's price to book ratio was 156.6× on Oct 31, 2025, against 2.2× a year earlier. Over the last 5 years it ranged from 0.4× to 156.6×, with a median of 2.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Oct 31, 2025156.6×+153.4
2024Dec 31, 20243.3×+2.7
2023Dec 29, 20230.6×+0.1
2022Dec 30, 20220.5×−1.5
2021Dec 31, 20212.0×−2.6
2020Dec 31, 20204.6×+0.7
2019Dec 31, 20194.0×−3.5
2018Dec 31, 20187.5×−10.7
2017Dec 29, 201718.2×+2.2
2016Dec 30, 201615.9×–

More Insight Molecular Diagnostics figures

See a number that looks wrong?